Annexon secures credit facility of up to $200 million from Oxford Finance

Annexon, Inc. (Nasdaq: ANNX) said on July 30, 2026 that it entered into a strategic credit facility agreement with Oxford Finance LLC for up to $200 million. Oxford Finance describes itself as a specialty finance firm providing senior secured loans to public and private companies. Annexon drew an initial $50 million at closing. Kirk Andrews, managing director of Oxford Finance, called the facility milestone-based and said it reflects the lender's confidence in Annexon's strategy and execution.

The facility terms and who is involved

Of the $200 million, $100 million becomes available when Annexon reaches certain milestones tied to its registrational programs for vonaprument and tanruprubart. The remaining $50 million is available subject to lender approval. The release gives no interest rate, maturity or collateral terms, so the cost of the money and the security Oxford takes cannot be judged from it.

The release names no placement agent, underwriter or financing advisor. The only other firm it names is LifeSci Advisors, which is listed as Annexon's investor contact. Oxford Finance is the lender. The release says Oxford has provided financing for over 20 years, has worked with over 750 companies and has originated more than $18 billion in loans since 2002. Those are Oxford's own figures.

Annexon's chief executive, Douglas Love, called the facility a source of "non-dilutive capital". The release does not mention warrants or any other equity component, so the company's "non-dilutive" label cannot be checked against the release's terms.

Cash burn against the new money

The company's 2025 annual report, filed March 30, 2026, shows research and development expense of $184.7 million in 2025, up from $119.4 million in 2024. The net loss widened to $206.7 million in 2025 from $138.2 million in 2024. Cash used in operations rose to $186.4 million in 2025 from $118.0 million in 2024.

At the end of 2024 the company held $49.5 million in cash and cash equivalents and $262.5 million in short-term investments. The $50 million drawn at closing is smaller than the cash used in operations in 2025, and the rest of the facility depends on milestones or lender approval.

The release itself lists a history of net operating losses among its risks. It also warns that the company's product candidates may not receive regulatory approval, including if the FDA decides the submission package is not sufficient or asks for additional data in patients that are not feasible to obtain.

The programs behind the milestones

Annexon describes itself as advancing a next generation platform of targeted immunotherapies for neuroinflammatory diseases that affect nearly 10 million people worldwide. Its work centers on C1q, which the company calls the initiating molecule of a potent inflammatory pathway that can cause tissue damage when misdirected.

Oxford's Andrews said Annexon is advancing an approach to complement-driven neuroinflammatory disease with two programs approaching registration. The release describes both programs as approaching registration, not as registered. It also gives no dates for the registrational milestones that unlock the $100 million.

What comes next

Annexon said the facility strengthens its capacity to prepare for the potential global commercialization of vonaprument and tanruprubart. The release's forward-looking section says the company could draw up to an additional $150 million under the facility. Both the milestone amount and the amount subject to lender approval depend on steps the release does not date.

Until those steps happen, the facility is a commitment of up to $200 million with $50 million drawn, and the release gives no timeline for the milestones that unlock the rest.

Report an error

Companies in this story

ANNXAnnexon, Inc.NASDAQ · United StatesOpen the starter desk